Результаты поиска

Onco-Hem Connectome-Network-Based Phenotyping of Polypharmacy and Drug-Drug Interactions in Onco-Hematological Inpatients.

We introduce the Onco-Hem Connectome (OHC), a patient similarity network (PSN) designed to organize real-world hemato-oncology inpatients by exploratory phenotypes with potential clinical utility. Background: Polypharmacy and drug-drug interactions (DDIs) are pervasive in hemato-oncology and vary with comorbidity and treatment intensity. Methods: We retrospectively analyzed a 2023 single-center cohort of 298 patients (1158 hospital episodes). Standardized feature vectors combined demographics, comorbidity (Charlson, Elixhauser), comorbidity polypharmacy score (CPS), aggregate DDI severity scor

Совпадение в полном тексте источника
… For this women-enriched phenotype, a pharmacotherapy focused on lymphoma is indicated, including premedication with antiemetics and corticosteroids, neuropathy vigilance for vinca alkaloids, and cardiotoxicity surveillance for anthracyclines [ 90 , 91 , 92 , 93 , 94 ]. … Bortezomib-based chemotherapy for multiple myeloma patients without comorbid cardiovascular disease shows no cardiotoxicity Clin. Lymphoma Myeloma Leuk. 2018 18 796 802 10.1016/j.clml.2018.08.004 30217616 54. Sandherr M. Hentrich M. von Lilienfeld-Toal M. Massenkeil G. Neumann S. Penack O. …

The Relationship Between Obesity and Cancer: Epidemiology, Pathophysiology, and the Effect of Obesity Treatment on Cancer.

There is growing evidence relating to the risk of cancer in people with obesity. Obesity is already established as one of the strongest predisposing factors to cancer, and 'obesity-related' cancers have been defined in previous studies. In this review article, we examine the epidemiological relationship and describe the potential pathophysiological mechanisms that underpin the association between obesity and cancer. These include hormonal and growth factors that are in abundance in persons living with obesity and thereby increase cancer risk. Additionally, the increased disposition towards chr

Совпадение в полном тексте источника
… A meta-analysis showed that obesity was linked to a 47% increased risk of cardiotoxicity in women with early breast cancer who received trastuzumab and anthracyclines [ 68 ]. Obesity has also been found to exacerbate radiation-related toxicities. … Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. J. Clin. Oncol. 2016;34:3157–3165. doi: 10.1200/JCO.2016.67.4846. 69. Xie Y., Wang Q., Hu T., Chen R., Wang J., Chang H., Cheng J. …

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

We conducted a phase 1/2 study of single-agent carfilzomib in Japanese patients with relapsed/refractory multiple myeloma. Safety, pharmacokinetics and pharmacodynamics of carfilzomib were examined in phase 1. The primary endpoint in phase 2 was the overall response rate (ORR). Carfilzomib was administered in a twice-weekly, consecutive-day dosing schedule. In Phase 1, doses of 15 or 20 mg/m(2) were administered on this schedule or 20 mg/m(2) on Days 1 and 2 of Cycle 1 and then 27 mg/m(2) in the 20/27 mg/m(2) cohort. Patients had a median of five prior therapies, including bortezomib and an im

Совпадение в полном тексте источника
… Cardiotoxicities have been unexpectedly induced by PIs (Voortman & Giaccone, 2006 ; Orciuolo et al , 2007 ). … Orciuolo, E. , Buda, G. , Cecconi, N. , Galimberti, S. , Versari, D. , Cervetti, G. , Salvetti, A. & Petrini, M. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 138, 396–397. Papadopoulos, K.P. , Burris, H.A. …

Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study.

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphalan) is the standard conditioning therapy, but clinical carmustine supply shortages have necessitated the search for alternatives. This study compared the toxicity and transplant outcomes of four carmustine-substituted conditioning regimens. We retrospectively analyzed 80 lymphoma patients who underwent ASCT between January 2018 and December 2023. Patients received one

Совпадение в полном тексте источника
… Specifically, the SEAM regimen was associated with more frequent BNP elevation, suggesting a potential risk of cardiotoxicity. The BeEAM regimen led to universal febrile neutropenia, higher platelet transfusion needs, and prolonged hospital stays. … This cardiotoxicity may be related to cyclophosphamide (CTX) and etoposide (VP‑16). …

Effect of N-Acetylcysteine on Cisplatin Toxicity: A Review of the Literature.

N-acetylcysteine (NAC) is a membrane-permeable cysteine precursor capable of enhancing the intracellular cysteine pool, enhancing cellular glutathione (GSH) synthesis, and thus potentiating the endogenous antioxidant mechanism. Late administration of NAC after cisplatin has been shown in different in vivo studies to reduce the side effects caused by various toxicities at different levels without affecting the antitumor efficacy of platinum, improving total and enzymatic antioxidant capacity and decreasing oxidative stress markers. These characteristics provide NAC with a rationale as a potenti

Совпадение в полном тексте источника
… While less frequent, other side effects include cardiotoxicity, hepatotoxicity, retinal toxicity, inappropriate antidiuretic hormone syndrome, hypersensitivity reactions, and reproductive toxicity, which may still occur in some cases. 4 , 20 , 21 , 24 Nephrotoxicity Approximately 25–35% of adults experience … The effects of N-acetylcysteine on cisplatin-induced cardiotoxicity. Bratisl Lek Listy . 2019;120(6):423–428. doi: 10.4149/BLL_2019_068 87. Rosic G, Selakovic D, Joksimovic J, et al. …

Carfilzomib for relapsed and refractory multiple myeloma.

Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory disease. Several new therapeutics have been developed in the last few years, including carfilzomib, a second-generation proteasome inhibitor (PI) that has been approved by the US Food and Drug Administration (FDA) in the setting of relapsed and/or refractory MM, as a single agent with or without dexamethasone, and in combination with lenalidomide in 2012 and 2015, respectively. Other promising combinations with carfilzomib are bei

Совпадение в полном тексте источника
… In sum, 17% reported cardiotoxicity: 9% in the bortezomib and 20% in the carfilzomib group. Baseline cardiac characteristics of value to predict cardiac AEs were not found. … Dimopoulos et al investigated the possible cardiotoxic effects of carfilzomib in 60 patients by performing serial echocardiography: 12% of patients experienced a reduction in left ventricular ejection fraction, which increased in time from 5% at 3 months till 12% at 15 months, and 23.5% of patients with …

Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.

New cases of invasive cancer in the United States occur among nearly 1.5 million people annually. In 2007, more than 1,500 people died per day with this diagnosis. Cancer is responsible for nearly one in every four deaths reported in the country. Enormous amounts of money and research have been, and are being spent, in an attempt to improve these numbers. While prevention and early detection remain the key to long-term success, treatment in the neo-adjuvant, adjuvant and metastatic settings still centre around two main treatment modalities - radiation therapy and chemotherapy. This article wil

Совпадение в полном тексте источника
… A review of the spectrum and reversibility of the cardiotoxicity observed in the adjuvant trastuzumab trials was recently reported [ 47 ]. … Herceptin 2008 46 Gianni L Herman EH Lipshultz SE Anthracycline cardiotoxicity: from bench to bedside J Clin Oncol 2008 26 22 3777 84 18669466 10.1200/JCO.2007.14.9401 PMC3018290 47 Telli ML Hunt SA Carlson RW Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J …

CircRNA ITCH: Insight Into Its Role and Clinical Application Prospect in Tumor and Non-Tumor Diseases.

CircRNA E3 ubiquitin protein ligase (ITCH) (circRNA ITCH, circ-ITCH), a stable closed-loop RNA derived from the 20q11.22 region of chromosome 20, is a new circRNA discovered in the cytoplasm in recent decades. Studies have shown that it does not encode proteins, but regulates proteins expression at different levels. It is down-regulated in tumor diseases and is involved in a number of biological activities, including inhibiting cell proliferation, migration, invasion, and promoting apoptosis. It can also alter disease progression in non-tumor disease by affecting the cell cycle, inflammatory r

Совпадение в полном тексте источника
… The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity through Upregulating SIRT6, Survivin, and SERCA2a. Circ. … Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18 (11), 1639–1642. 10.1038/nm.2919 Zhang Y., Li Y., Wang Q., Su B., Xu H., Sun Y., et al. (2020). Role of RASA1 in cancer: A review and update (Review). Oncol. …

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

A new era of cancer immunotherapy: vaccines and miRNAs.

Cancer immunotherapy has transformed the treatment landscape, introducing new strategies to fight various types of cancer. This review examines the important role of vaccines in cancer therapy, focusing on recent advancements such as dendritic cell vaccines, mRNA vaccines, and viral vector-based approaches. The relationship between cancer and the immune system highlights the importance of vaccines as therapeutic tools. The discussion covers tumor cell and dendritic cell vaccines, protein/peptide vaccines, and nucleic acid vaccines (including DNA, RNA, or viral vector-based), with a focus on th

Совпадение в полном тексте источника
… The use of other medications that may raise the incidence of anthracycline-induced cardiotoxicity raises the risk of it. … The greatest biomarker for doxorubicin-induced cardiotoxicity was found to be miR-1, which exhibited significantly higher expression than other miRNAs and improved the assessment of cardiac injuries in patients with cardiotoxicity as opposed to cardiac troponin I (cTnI) [ 103 ]. …

Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery.

Drug repurposing is a method of investigating new therapeutic applications for previously approved medications. This repurposing approach to "old" medications is now highly efficient, simple to arrange, and cost-effective and poses little risk of failure in treating a variety of disorders, including cancer. Drug repurposing for cancer therapy is currently a key topic of study. It is a way of exploring recent therapeutic applications for already-existing drugs. Theoretically, the repurposing strategy has various advantages over the recognized challenges of creating new molecular entities, inclu

Совпадение в полном тексте источника
… In addition, another productive antibiotic that has low cardiotoxicity is pirarubicin. It is a particularly lipophilic molecule; thus, the absorption rate is considerably elevated. … Additionally, it is in a phase III trial and has minimal cardiotoxicity. It is used to treat aggressive NHL (non-Hodgkin lymphoma), which is cancer of the lymph tissue. 20 The cell cycle is modified in such a way as to produce an antiproliferative effect. …

Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.

Despite the uncertainty of the pathogenesis of systemic lupus erythematosus, novel small molecules targeting specific intracellular mechanisms of immune cells are being developed to reverse the pathophysiological processes. These targeted molecules have the advantages of convenient administration, lower production costs, and the lack of immunogenicity. The Janus kinases, Bruton's tyrosine kinases, and spleen tyrosine kinases are important enzymes for activating downstream signals from various receptors on immune cells that include cytokines, growth factor, hormones, Fc, CD40, and B-cell recept

Совпадение в полном тексте источника
… However, AEs such as cardiotoxicity (atrial and ventricular arrythmia, cardiomyopathy, hypertension) and bleeding (platelet dysfunction) may result in treatment interruption or discontinuation [ 81 ]. … Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol. 2022;15:321–331. doi: 10.1080/17474086.2022.2067526. 82. Thompson PA, Burger JA. …

Integrative Hematology: State of the Art.

Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient's therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical s

Совпадение в полном тексте источника
… It also reduces the cardiotoxicity of arsenic trioxide, a drug used in acute promyelocytic leukemia, showing promise for its use in this patient setting [ 60 ]. … Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance Theranostics 2016 6 1277 1292 10.7150/thno.15133 27375779 PMC4924499 32. Han D.H. Kim J.H. …

Alpha-mangostin Amliorates Apoptosis, воспаление и окисляющий стресс в результате разложения Cuprizon в C57BL/6 Мыши.

ВВЕДЕНИЕ: Согласно сообщениям, альфа-мангостин (α-MG), самый изобилийный ксантон, найденный в Гарцинии Мангостана Линн, обладает мощными антиоксидантами и антивоспламеняющимися свойствами. Цель этого исследования заключалась в изучении нейрозащитного воздействия α-MG на вызванную кубической зоной (CZ) демиелинизацию в корпусе каллосум (CC) мышей, ставшей установившейся моделью животных для множественного склероза (MS). МЕТОДЫ: Взрослая женщина C57BL/6 Мыши были накормлены чау, в котором содержится 0.4% (w/w) CZ для 5 недель. Животные были произвольно назначены six группы: (1) контрольная групп

Совпадение в полном тексте источника
… Additionally, α-MG significantly lowered MDA levels and increased GSH in cardiac tissue following doxorubicin-induced cardiotoxicity in rats ( Eisvand et al., 2022 ). … In a model of doxorubicin-induced cardiotoxicity, α-MG (100 mg/kg) reduced apoptosis through decreased levels of cleaved caspase-3 and a lower Bax/Bcl-2 ratio ( Eisvand et al., 2022 ). …

Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan.

BackgroundCarfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression-free survival (PFS); however, treatment with carfilzomib results in a higher incidence of cardiovascular and renal toxicity. More than 70% of patients with RRMM in clinical practice do not meet the eligibility criteria for randomized clinical trials (RCT). OS and PFS are negatively influenced by complications, concomitant medications and prior treatments. Therefore, we assessed the risk factors influencing the

Совпадение в полном тексте источника
… Although common, cardiovascular events with carfilzomib did not necessarily require dosing discontinuation. 2 A meta‐analysis evaluating carfilzomib cardiotoxicity reported that high‐dose regimens were associated with cardiotoxicity. 17 In addition, comorbid hypertension was a major contributor to carfilzomib‐associated …

Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It?

Overcoming the limited bioavailability and extensive metabolism of effective in vitro drugs remains a challenge that limits the translation of promising drugs into clinical trials. Resveratrol, despite its well-reported therapeutic benefits, is not metabolically stable and thus has not been utilized as an effective clinical drug. This is because it needs to be consumed in large amounts to overcome the burdens of bioavailability and conversion into less effective metabolites. Herein, we summarize the more relevant approaches to modify resveratrol, aiming to increase its biological and therapeut

Совпадение в полном тексте источника
… The study demonstrated that the simultaneous delivery of doxorubicin and resveratrol in pluronic micelles enhanced the cytotoxicity of doxorubicin in lymphoma cells and lowered its cardiotoxicity in cardiac cells [ 156 ]. … The ability of RSV-loaded SLNPs to attenuate doxorubicin-induced cardiotoxicity was analyzed. In fact, RSV is known to attenuate the cardiotoxicity of doxorubicin, a chemotherapeutic drug that is clinically used to treat breast and lung cancer. …

Post-Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation.

Post-transplant cyclophosphamide (PT-CY) remains the standard of care for graft-versus-host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations. Post-transplant bendamustine (PT-BEN) has been investigated as a biologically distinct alternative. In stringent haploidentical murine models, PT-BEN uncoupled GvHD from graft-versus-leukemia (GvL) effects through mechanisms centered on myeloid modulation and preservation of innate imm

Совпадение в полном тексте источника
… Recent literature demonstrates that reduced‐dose PT‐CY alone accelerates engraftment and reduces toxicity including hemorrhagic cystitis and cardiotoxicity without compromising GvHD control [ 51 , 52 , 53 , 54 , 55 , 56 ]. … Hadjali R., Chevillon F., Sibilia B., et al., “Risk of Posttransplant Cyclophosphamide‐Related Cardiotoxicity in Allogeneic Stem Cell Transplantation,” Canadian Journal of Cardiology (2026). 48. Yeh J., Whited L., Saliba R. …

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.

Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidoge

Совпадение в полном тексте источника
… Elevation in MMP and tissue inhibitor of matrix metalloproteinase serum levels and tissue expression have been associated with renal and cardiac damage in AL 53 , 54 , suggesting that inhibition of the MMP pathway may mitigate the cardiotoxic effects of light chain amyloid fibril deposition. … A paradoxical increase in NT-proBNP has been described in AL patients on lenalidomide despite hematologic response and absence of cardiac symptoms, possibly reflecting IMiD-induced fluid retention as opposed to direct cardiotoxicity 101 , 102 . …

Nanotherapeutics in the EU: an overview on current state and future directions.

The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug's therapeutic index, and reduce a drug's immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most suc

Совпадение в полном тексте источника
… In addition, doxorubicin liposomal formulations have shown significantly reduced cardiotoxicity compared with free doxorubicin. 24 , 25 With DaunoXome® (Gilead Sciences Ltd, Co, Cork, Ireland), daunorubicin was incorporated into a liposomal carrier system, again to reduce the risk of acute and cumulative … Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007;2(4):567–583. 29. Fukui H, Koike T, Nakagawa T, et al. …

Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.

Cancer continues to pose a global health challenge, with conventional therapies often limited by non-specific toxicity, drug resistance, and an inadequate therapeutic index. Nanotechnology offers transformative opportunities by enabling targeted drug delivery, improved pharmacokinetics, and integrated diagnostic-therapeutic platforms (termed nanotheranostics). This review highlights key nanocarrier systems including liposomes, polymeric nanoparticles, dendrimers, inorganic nanostructures, carbon-based materials, extracellular vesicles, and hybrid platforms with a focus on human studies and cli